Tower Research Capital LLC TRC Has $33,000 Stake in NewAmsterdam Pharma (NASDAQ:NAMS)

Tower Research Capital LLC TRC reduced its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 83.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 1,297 shares of the company’s stock after selling 6,485 shares during the quarter. Tower Research Capital LLC TRC’s holdings in NewAmsterdam Pharma were worth $33,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the business. Barclays PLC raised its stake in NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after acquiring an additional 7,199 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of NewAmsterdam Pharma by 176.9% in the third quarter. JPMorgan Chase & Co. now owns 22,351 shares of the company’s stock valued at $371,000 after purchasing an additional 14,280 shares during the last quarter. HB Wealth Management LLC bought a new position in shares of NewAmsterdam Pharma in the fourth quarter valued at about $224,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of NewAmsterdam Pharma during the 4th quarter worth about $503,000. Finally, Jennison Associates LLC boosted its holdings in shares of NewAmsterdam Pharma by 291.9% during the 4th quarter. Jennison Associates LLC now owns 3,998,541 shares of the company’s stock worth $102,763,000 after buying an additional 2,978,263 shares during the period. 89.89% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director James N. Topper purchased 1,135 shares of the stock in a transaction dated Wednesday, March 26th. The shares were purchased at an average cost of $22.49 per share, with a total value of $25,526.15. Following the completion of the acquisition, the director now owns 3,013,569 shares in the company, valued at $67,775,166.81. This represents a 0.04% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CAO Louise Frederika Kooij sold 150,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the transaction, the chief accounting officer now directly owns 15,000 shares of the company’s stock, valued at approximately $305,550. This represents a 90.91% decrease in their position. The disclosure for this sale can be found here. Insiders own 19.50% of the company’s stock.

NewAmsterdam Pharma Price Performance

Shares of NewAmsterdam Pharma stock opened at $18.75 on Thursday. The business has a 50-day simple moving average of $19.25 and a 200 day simple moving average of $21.22. The firm has a market capitalization of $2.06 billion, a price-to-earnings ratio of -9.97 and a beta of 0.01. NewAmsterdam Pharma has a one year low of $14.06 and a one year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.04). The company had revenue of $2.98 million for the quarter, compared to analyst estimates of $1.46 million. On average, sell-side analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on NAMS shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Scotiabank lifted their price target on NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Thursday, February 27th. Needham & Company LLC decreased their price objective on NewAmsterdam Pharma from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, May 8th. Finally, UBS Group set a $41.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, March 3rd. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $43.00.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.